Therapy Areas: AIDS & HIV
Ascletis Pharma Inc submits third HCV drug ASC21 IND with NMPA
3 January 2019 - Biotechnology company Ascletis Pharma Inc (1672.HK) said on Wednesday that it has filed its investigational new drug application (IND) for its third HCV drug ASC21 successfully with t...
Hookipa Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead
2 January 2019 - - Austrian clinical stage biopharmaceutical company Hookipa Pharma Inc has achieved its first research milestone in its collaboration and license agreement with US-based Gilead Scienc...
Viriom starts the first phase one clinical trial of HIV treatment VM1500A
21 December 2018 - United States-based Viriom Inc announced yesterday that it has started the first phase one clinical trial of the long-acting nanoformulation of VM1500A in HIV-uninfected volunteers,...
DelSiTech signs license agreement with Innovare R&D
20 December 2018 - Finland-based DelSiTech has signed a world-wide, exclusive license agreement with Innovare R&D, a Mexico-based pharma company, it was reported yesterday.The contract has been si...
DelSiTech & Innovare partnership to develop long acting HIV therapy
18 December 2018 - Finnish drug company DelSiTech Ltd reported on Monday the launch of a world-wide, exclusive licence agreement for the use of its Silica Matrix drug delivery platform in the developm...
Mayne Pharma passes US FDA approval of Tolsura (SUBA-itraconazole capsules) for certain fungal infections
12 December 2018 - Medicines company Mayne Pharma Group Limited (ASX:MYX) reported on Tuesday the receipt of the US Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for t...
Related Headlines

Hookipa and DarwinHealth Enter into a Research Collaboration and License Agreement to Discover and Prioritize Novel Immunogenic, Tumor-Specific Cryptic Antigens

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for RP-L102 Gene Therapy for Fanconi Anemia

Rocket Pharmaceuticals passes US FDA RMAT & FTD for RP-L102 to treat Fanconi Anemia

Parexel Appoints New Members to Its Board of Directors

Bridge Therapeutics adds Dr Steven Passik to Scientific Advisory Board

AstraZeneca agrees to offload Alvesco (ciclesonide), Omnaris and Zetonna rights to Covis Pharma

ViiV Healthcare reveals positive results for phase three BRIGHTE study of Fostemsavir

Gilead Show 96-Week Results From Phase 3 Study of Biktarvy(Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Janssen Touts Positive Long-Term Efficacy and Safety of Symtuza (D/C/F/TAF) in Treatment-Naïve Adults with HIV-1

NanoViricides Inc names new Independent Director

Aelix Therapeutics, Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

Ansun Biopharma names new chief medical officer

US FDA allows marketing of first self-fitting Bose Hearing Aid

Merck's Delstrigo achieves primary efficacy endpoint in phase three Drive-Shift study

Merck Releases Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating Delstrigo for the Treatment of HIV-1 in Treatment-Naïve Patients